Table of Contents Author Guidelines Submit a Manuscript
Disease Markers
Volume 2017, Article ID 8165219, 8 pages
https://doi.org/10.1155/2017/8165219
Research Article

The Relationship between VEGFA and TGFB1 Polymorphisms and Target Lesion Revascularization after Elective Percutaneous Coronary Intervention

12nd Department of Cardiology and Angiology, Silesian Center for Heart Disease, Zabrze, Poland
23rd Department of Cardiology, School of Medicine with the Division of Dentistry in Zabrze, Medical University of Silesia in Katowice, Silesian Center for Heart Disease, Zabrze, Poland
3Department of Medical and Molecular Biology, School of Medicine with the Division of Dentistry in Zabrze, Medical University of Silesia, Katowice, Poland

Correspondence should be addressed to Tadeusz Osadnik; lp.sccs@kindaso.zsuedat

Received 23 January 2017; Revised 10 June 2017; Accepted 14 June 2017; Published 24 July 2017

Academic Editor: Michele Malaguarnera

Copyright © 2017 Tadeusz Osadnik et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. W. G. Feero, A. E. Guttmacher, C. J. O’Donnell, and E. G. Nabel, “Genomics of cardiovascular disease,” The New England Journal of Medicine, vol. 365, no. 22, pp. 2098–2109, 2011. View at Publisher · View at Google Scholar
  2. J. Wasilewski, T. Osadnik, S. Peryt Stawiarska, and L. Poloński, “The role of haemodynamic factors in the development of in-stent restenosis,” Kardiologia Polska, vol. 70, no. 11, pp. 1194–1198, 2012. View at Google Scholar
  3. W. S. Weintraub, “The pathophysiology and burden of restenosis,” The American Journal of Cardiology, vol. 100, no. 5, pp. 3K–9K, 2007. View at Publisher · View at Google Scholar · View at Scopus
  4. T. Osadnik, K. Bujak, and A. Lekston, “Is GLUT1 a potential target for in-stent restenosis treatment?” International Journal of Cardiology, vol. 223, pp. 199-200, 2016. View at Publisher · View at Google Scholar · View at Scopus
  5. T. Osadnik, J. Strzelczyk, K. Bujak et al., “Functional polymorphism rs710218 in the gene coding GLUT1 protein is associated with in-stent restenosis,” Biomarkers in Medicine, vol. 9, no. 8, pp. 743–750, 2015. View at Publisher · View at Google Scholar · View at Scopus
  6. T. Osadnik, J. K. Strzelczyk, M. Fronczek et al., “Relationship of the rs1799752 polymorphism of the angiotensin-converting enzyme gene and the rs699 polymorphism of the angiotensinogen gene to the process of in-stent restenosis in a population of Polish patients with stable coronary artery disease,” Advances in Medical Sciences, vol. 61, no. 2, pp. 276–281, 2016. View at Publisher · View at Google Scholar · View at Scopus
  7. J. W. Jukema, J. J. W. Verschuren, T. A. N. Ahmed, and P. H. A. Quax, “Restenosis after PCI. Part 1: pathophysiology and risk factors,” Nature Reviews Cardiology, vol. 9, no. 1, pp. 53–62, 2012. View at Publisher · View at Google Scholar · View at Scopus
  8. C.-C. Szeto, K.-M. Chow, P. Poon, C. Y.-K. Szeto, T. Y.-H. Wong, and P. K.-T. Li, “Genetic polymorphism of VEGF: impact on longitudinal change of peritoneal transport and survival of peritoneal dialysis patients,” Kidney International, vol. 65, no. 5, pp. 1947–1955, 2004. View at Publisher · View at Google Scholar · View at Scopus
  9. G. C. Martelossi Cebinelli, K. Paiva Trugilo, S. Badaró Garcia, and K. Brajão de Oliveira, “TGF-β1 functional polymorphisms: a review,” European Cytokine Network, vol. 27, no. 4, pp. 81–89, 2016. View at Publisher · View at Google Scholar
  10. T. Osadnik, J. K. Strzelczyk, R. Reguła et al., “The relationships between polymorphisms in genes encoding the growth factors TGF-β1, PDGFB, EGF, bFGF and VEGF-A and the restenosis process in patients with stable coronary artery disease treated with bare metal stent,” PloS One, vol. 11, no. 3, article e0150500, 2016. View at Publisher · View at Google Scholar · View at Scopus
  11. M. Yang, M. Zhu, L. Tang et al., “Polymorphisms of TGFβ-1 and TGFBR2 in relation to coronary artery disease in a Chinese population,” Clinical Biochemistry, vol. 49, no. 12, pp. 873–878, 2016. View at Publisher · View at Google Scholar · View at Scopus
  12. W. M. Howell, S. Ali, M. J. Rose-Zerilli, and S. Ye, “VEGF polymorphisms and severity of atherosclerosis,” Journal of Medical Genetics, vol. 42, no. 6, pp. 485–490, 2005. View at Publisher · View at Google Scholar · View at Scopus
  13. D. R. Morris, J. V. Moxon, E. Biros, S. M. Krishna, and J. Golledge, “Meta-analysis of the association between transforming growth factor-beta polymorphisms and complications of coronary heart disease,” PloS One, vol. 7, no. 5, article e37878, 2012. View at Publisher · View at Google Scholar
  14. Y. Chen, P. T. Dawes, J. C. Packham, and D. L. Mattey, “Interaction between smoking and polymorphism in the promoter region of the VEGFA gene is associated with ischemic heart disease and myocardial infarction in rheumatoid arthritis,” The Journal of Rheumatology, vol. 38, no. 5, pp. 802–809, 2011. View at Publisher · View at Google Scholar · View at Scopus
  15. T. Osadnik, J. Wasilewski, A. Lekston et al., “Comparison of modification of diet in renal disease and chronic kidney disease epidemiology collaboration formulas in predicting long-term outcomes in patients undergoing stent implantation due to stable coronary artery disease,” Clinical Research in Cardiology, vol. 103, no. 7, pp. 569–576, 2014. View at Publisher · View at Google Scholar · View at Scopus
  16. P. Trzeciak, M. Gierlotka, M. Gąsior et al., “In-hospital and 12-month outcomes after acute coronary syndrome treatment in patients aged<40 years of age (from the Polish Registry of Acute Coronary Syndromes),” The American Journal of Cardiology, vol. 114, no. 2, pp. 175–180, 2014. View at Publisher · View at Google Scholar · View at Scopus
  17. T. Osadnik, J. K. Strzelczyk, A. Lekston et al., “The association of functional polymorphisms in genes encoding growth factors for endothelial cells and smooth muscle cells with the severity of coronary artery disease,” BMC Cardiovascular Disorders, vol. 16, no. 1, p. 218, 2016. View at Publisher · View at Google Scholar · View at Scopus
  18. D. J. Stekhoven and P. Bühlmann, “MissForest—non-parametric missing value imputation for mixed-type data,” Bioinformatics, vol. 28, no. 1, pp. 112–118, 2012. View at Publisher · View at Google Scholar · View at Scopus
  19. J. R. González, L. Armengol, X. Solé et al., “SNPassoc: an R package to perform whole genome association studies,” Bioinformatics, vol. 23, no. 5, pp. 654-655, 2007. View at Publisher · View at Google Scholar · View at Scopus
  20. D. J. Stekhoven, “MissForest: nonparametric missing value imputation using random forest,” R Package Version, vol. 1, no. 4, 2013. View at Google Scholar
  21. R Core Team, R: A Language and Environment for Statistical Computing, R Foundation for Statistical Computing, Vienna, Austria, 2013, http://www.R-project.org/.
  22. T. P. Smith, “Atherosclerosis and restenosis: an inflammatory issue,” Radiology, vol. 225, no. 1, pp. 10–12, 2002. View at Publisher · View at Google Scholar
  23. M. Kollum, S. Kaiser, R. Kinscherf, J. Metz, W. Kübler, and C. Hehrlein, “Apoptosis after stent implantation compared with balloon angioplasty in rabbits. Role of macrophages,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 17, no. 11, pp. 2383–2388, 1997. View at Publisher · View at Google Scholar
  24. W. Liu, Y. Liu, H. Jiang et al., “Plasma levels of interleukin 18, interleukin 10, and matrix metalloproteinase-9 and -137G/C polymorphism of interleukin 18 are associated with incidence of in-stent restenosis after percutaneous coronary intervention,” Inflammation, vol. 36, no. 5, pp. 1129–1135, 2013. View at Publisher · View at Google Scholar · View at Scopus
  25. R. Y. L. Zee, H. H. Hegener, A. Fernandez-Cruz, and K. Lindpaintner, “C-reactive protein gene polymorphisms and the incidence of post-angioplasty restenosis,” Atherosclerosis, vol. 176, no. 2, pp. 393–396, 2004. View at Publisher · View at Google Scholar · View at Scopus
  26. T. Dzielski and P. Buszman, “Inflammation and restenosis following coronary stent implantation,” Postepy Kardiologii Interwencyjnej, vol. 1, no. 1, pp. 67–70, 2005. View at Google Scholar
  27. A. Tedgui and Z. Mallat, “Anti-inflammatory mechanisms in the vascular wall,” Circulation Research, vol. 88, no. 9, pp. 877–887, 2001. View at Google Scholar
  28. S. Redondo, E. Ruiz, C. G. Santos-Gallego, E. Padilla, and T. Tejerina, “Pioglitazone induces vascular smooth muscle cell apoptosis through a peroxisome proliferator-activated receptor-gamma, transforming growth factor-beta1, and a Smad2-dependent mechanism,” Diabetes, vol. 54, no. 3, pp. 811–817, 2005. View at Google Scholar
  29. S. Redondo, J. Navarro-Dorado, M. Ramajo, Ú. Medina, and T. Tejerina, “The complex regulation of TGF-β in cardiovascular disease,” Vascular Health and Risk Management, vol. 8, pp. 533–539, 2012. View at Publisher · View at Google Scholar · View at Scopus
  30. Y. Tang, X. Yang, R. E. Friesel, C. P. H. Vary, and L. Liaw, “Mechanisms of TGF-β-induced differentiation in human vascular smooth muscle cells,” Journal of Vascular Research, vol. 48, no. 6, pp. 485–494, 2011. View at Publisher · View at Google Scholar · View at Scopus
  31. D. J. Grainger, L. Wakefield, H. W. Bethell, R. W. Farndale, and J. C. Metcalfe, “Release and activation of platelet latent TGF-beta in blood clots during dissolution with plasmin,” Nature Medicine, vol. 1, no. 9, pp. 932–937, 1995. View at Publisher · View at Google Scholar · View at Scopus
  32. M. Suthanthiran, B. Li, J. O. Song et al., “Transforming growth factor-beta 1 hyperexpression in African-American hypertensives: a novel mediator of hypertension and/or target organ damage,” Proceedings of the National Academy of Sciences of the United States of America, vol. 97, no. 7, pp. 3479–3484, 2000. View at Publisher · View at Google Scholar · View at Scopus
  33. M. Yokota, S. Ichihara, T. L. Lin, N. Nakashima, and Y. Yamada, “Association of a T29—>C polymorphism of the transforming growth factor-beta1 gene with genetic susceptibility to myocardial infarction in Japanese,” Circulation, vol. 101, no. 24, pp. 2783–2787, 2000. View at Publisher · View at Google Scholar
  34. S. Pooja, A. Francis, S. Rajender et al., “Strong impact of TGF-β1 gene polymorphisms on breast cancer risk in Indian women: a case-control and population-based study,” PloS One, vol. 8, no. 10, article e75979, 2013. View at Publisher · View at Google Scholar · View at Scopus
  35. S. Xu, S. Yang, G. Sun, W. Huang, and Y. Zhang, “Transforming growth factor-beta polymorphisms and serum level in the development of osteosarcoma,” DNA and Cell Biology, vol. 33, no. 11, pp. 802–806, 2014. View at Publisher · View at Google Scholar · View at Scopus
  36. D. Kajdaniuk, B. Marek, H. Borgiel-Marek, and B. Kos-Kudła, “Transforming growth factor β1 (TGFβ1) in physiology and pathology,” Endokrynologia Polska, vol. 64, no. 5, pp. 384–396, 2013. View at Publisher · View at Google Scholar · View at Scopus
  37. B. Hudzik, J. Szkodzinski, W. Romanowski et al., “No predictive value of serum interleukin-6 and transforming growth factor-beta1 in identifying patients with a first restenosis, recurrent restenosis or a history of restenosis,” European Cytokine Network, vol. 20, no. 3, pp. 135–139, 2009. View at Publisher · View at Google Scholar · View at Scopus
  38. J. Szkodzinski, A. Blazelonis, K. Wilczek et al., “The role of interleukin-6 and transforming growth factor-beta1 in predicting restenosis within stented infarct-related artery,” International Journal of Immunopathology and Pharmacology, vol. 22, no. 2, pp. 493–500, 2009. View at Publisher · View at Google Scholar
  39. I.-M. Chung, J. Kim, Y. K. Pak et al., “Blockade of TGF-β by catheter-based local intravascular gene delivery does not alter the in-stent neointimal response, but enhances inflammation in pig coronary arteries,” International Journal of Cardiology, vol. 145, no. 3, pp. 468–475, 2010. View at Publisher · View at Google Scholar · View at Scopus
  40. H. Tao, G. Chen, G. Cheng, and X. Shan, “The haplotype of the TGFβ1 gene associated with cerebral infarction in Chinese,” The Canadian Journal of Neurological Sciences, vol. 39, no. 5, pp. 626–631, 2012. View at Google Scholar
  41. M. Cruz, J. M. Fragoso, E. Alvarez-León et al., “The TGF-B1 and IL-10 gene polymorphisms are associated with risk of developing silent myocardial ischemia in the diabetic patients,” Immunology Letters, vol. 156, no. 1-2, pp. 18–22, 2013. View at Publisher · View at Google Scholar · View at Scopus
  42. J. M. Fragoso, J. Zuñiga-Ramos, M. Arellano-González et al., “The T29C (rs1800470) polymorphism of the transforming growth factor-β1 (TGF-β1) gene is associated with restenosis after coronary stenting in Mexican patients,” Experimental and Molecular Pathology, vol. 98, no. 1, pp. 13–17, 2015. View at Publisher · View at Google Scholar · View at Scopus
  43. S. M. Weis and D. A. Cheresh, “Pathophysiological consequences of VEGF-induced vascular permeability,” Nature, vol. 437, no. 7058, pp. 497–504, 2005. View at Publisher · View at Google Scholar · View at Scopus
  44. A. Hoeben, B. Landuyt, M. S. Highley, H. Wildiers, A. T. Van Oosterom, and E. A. De Bruijn, “Vascular endothelial growth factor and angiogenesis,” Pharmacological Reviews, vol. 56, no. 4, pp. 549–580, 2004. View at Publisher · View at Google Scholar · View at Scopus
  45. A. M. Duffy, D. J. Bouchier-hayes, and J. H. Harmey, “Vascular endothelial growth factor (VEGF) and its role in non-endothelial cells: autocrine signalling by VEGF,” in VEGF and Cancer, J. H. Harmey, Ed., Landes Bioscience, pp. 133–144, Landes Bioscience, Georgetown, Texas, USA, 2004. View at Google Scholar
  46. M. Shahbazi, A. A. Fryer, V. Pravica et al., “Vascular endothelial growth factor gene polymorphisms are associated with acute renal allograft rejection,” Journal of the American Society of Nephrology, vol. 13, no. 1, pp. 260–264, 2002. View at Publisher · View at Google Scholar
  47. Y. Wang, Q. Huang, J. Liu et al., “Vascular endothelial growth factor A polymorphisms are associated with increased risk of coronary heart disease: a meta-analysis,” Oncotarget, vol. 8, no. 18, pp. 30539–30551, 2017. View at Publisher · View at Google Scholar
  48. T.-H. Lin, C.-L. Wang, H.-M. Su et al., “Functional vascular endothelial growth factor gene polymorphisms and diabetes: effect on coronary collaterals in patients with significant coronary artery disease,” Clinica Chimica Acta, vol. 411, no. 21-22, pp. 1688–1693, 2010. View at Publisher · View at Google Scholar · View at Scopus
  49. G. H. Oliveira-Paula, R. Lacchini, V. Fontana, P. S. Silva, C. Biagi, and J. E. Tanus-Santos, “Polymorphisms in VEGFA gene affect the antihypertensive responses to enalapril,” European Journal of Clinical Pharmacology, vol. 71, no. 8, pp. 949–957, 2015. View at Publisher · View at Google Scholar · View at Scopus
  50. Z. Bagyura, L. Kiss, K. Hirschberg et al., “Association between VEGF gene polymorphisms and in-stent restenosis after coronary intervention treated with bare metal stent,” Disease Markers, vol. 2017, Article ID 9548612, 7 pages, 2017. View at Publisher · View at Google Scholar
  51. “Ensembl,” December 2016, http://www.ensembl.org/index.html.